4.8 Article

Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores

期刊

NATURE COMMUNICATIONS
卷 12, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-021-24082-z

关键词

-

资金

  1. Medical Research Council [UKDRI-3003]
  2. Alzheimer's Research UK
  3. Alzheimer's Society
  4. Welsh Government, Joint Programming for Neurodegeneration [MRC: MR/T04604X/1]
  5. Dementia Platforms UK [MRC: MR/L023784/2]
  6. MRC Centre for Neuropsychiatric Genetics and Genomics [MR/L010305/1]
  7. The Moondance Foundation
  8. KU Leuven (Methusalem grant)
  9. European Union [ERC-834682 CELLPHASE_AD]
  10. Fonds voor Wetenschappelijk Onderzoek
  11. Geneeskundige Stichting Koningin Elisabeth
  12. Opening the Future campaign of the Leuven Universitair Fonds
  13. Belgian Alzheimer Research Foundation
  14. Alzheimer's Association USA
  15. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant) [U01 AG024904]
  16. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  17. National Institute on Aging
  18. National Institute of Biomedical Imaging and Bioengineering
  19. AbbVie
  20. Alzheimer's Association
  21. Alzheimer's Drug Discovery Foundation
  22. Araclon Biotech
  23. BioClinica, Inc.
  24. Biogen
  25. Bristol-Myers Squibb Company
  26. CereSpir, Inc.
  27. Cogstate
  28. Eisai Inc.
  29. Elan Pharmaceuticals, Inc.
  30. Eli Lilly and Company
  31. EuroImmun
  32. F. Hoffmann-La Roche Ltd
  33. Genentech, Inc.
  34. Fujirebio
  35. GE Healthcare
  36. IXICO Ltd.
  37. Janssen Alzheimer Immunotherapy Research & Development, LLC
  38. Johnson & Johnson Pharmaceutical Research & Development LLC
  39. Lumosity
  40. Lundbeck
  41. Merck Co., Inc.
  42. Meso Scale Diagnostics, LLC
  43. NeuroRx Research
  44. Neurotrack Technologies
  45. Novartis Pharmaceuticals Corporation
  46. Pfizer Inc.
  47. Piramal Imaging
  48. Servier
  49. Takeda Pharmaceutical Company
  50. Transition Therapeutics
  51. The Canadian Institutes of Health Research
  52. NIA [P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, U01AG61356]
  53. Illinois Department of Public Health
  54. Translational Genomics Research Institute
  55. Wellcome Trust
  56. MRC
  57. UK Biobank Resource
  58. MRC [MR/L023784/2, UKDRI-1004, UKDRI-3003, MR/T04604X/1] Funding Source: UKRI

向作者/读者索取更多资源

Polygenic Risk Scores for Alzheimer's disease offer unique possibilities for reliably identifying individuals at high and low risk. The study shows that the best prediction accuracy is achieved with a model including APOE and a polygenic score excluding APOE. Standardizing PRS against the population mean makes individuals' scores comparable between studies.
Polygenic Risk Scores (PRS) for AD offer unique possibilities for reliable identification of individuals at high and low risk of AD. However, there is little agreement in the field as to what approach should be used for genetic risk score calculations, how to model the effect of APOE, what the optimal p-value threshold (pT) for SNP selection is and how to compare scores between studies and methods. We show that the best prediction accuracy is achieved with a model with two predictors (APOE and PRS excluding APOE region) with pT<0.1 for SNP selection. Prediction accuracy in a sample across different PRS approaches is similar, but individuals' scores and their associated ranking differ. We show that standardising PRS against the population mean, as opposed to the sample mean, makes the individuals' scores comparable between studies. Our work highlights the best strategies for polygenic profiling when assessing individuals for AD risk. While polygenic risk scores have been shown to be correlated with disease risk, there is little agreement on how the score should be calculated. Here the authors investigate risk scores for Alzheimer's disease, finding that the most effective approach includes an APOE score and a polygenic score excluding APOE.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据